Search

Lonza Group AG

Atidarymo kaina

SektoriusSveikatos priežiūra

574.8 1.13

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

567

Max

578.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

329M

Pardavimai

3.1B

P/E

Sektoriaus vid.

60.584

57.333

Pelnas, tenkantis vienai akcijai

4.31

Dividendų pajamingumas

0.74

Pelno marža

10.762

Darbuotojai

17,995

EBITDA

824M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+17.56% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.74%

2.63%

Kitas uždarbis

2025-07-23

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.2B

39B

Ankstesnė atidarymo kaina

573.67

Ankstesnė uždarymo kaina

574.8

Lonza Group AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-18 12:22; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

2024-12-12 09:26; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Streamlines Business With Capsules Unit Exit -- 2nd Update

2024-12-12 07:45; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Streamlines Business With Capsules Unit Exit -- Update

2024-12-12 06:52; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Streamlines Organizational Structure

2025-04-08 07:34; UTC

Rinkos pokalbiai

Lonza Well Protected From Tariffs -- Market Talk

2025-01-29 08:11; UTC

Rinkos pokalbiai
Uždarbis

Lonza's Outlook Looks Positive -- Market Talk

2025-01-29 07:22; UTC

Rinkos pokalbiai
Uždarbis

Lonza Had a Mixed Year Across Divisions -- Market Talk

2025-01-29 07:11; UTC

Rinkos pokalbiai
Uždarbis

Lonza's Results Don't Contain Any Surprises -- Market Talk

2025-01-29 06:26; UTC

Svarbiausios naujienos
Uždarbis

Lonza Posts Lower Sales, Earnings But Expects Capsules Business Rebound This Year

2025-01-16 10:32; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Lonza's Midterm Outlook Is Positive -- Market Talk

2024-12-16 22:03; UTC

Svarbiausios naujienos

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

2024-12-13 08:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Lonza Unlikely to Pursue Large Acquisitions -- Market Talk

2024-12-12 08:51; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Lonza's Exit of Capsules Business Is a Positive Move -- Market Talk

2024-12-12 08:02; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Lonza's Divestiture of Capsules Division Shouldn't Surprise -- Market Talk

2024-12-12 05:59; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Targets Dividend Pay-Out Ratio Between 35%-45%

2024-12-12 05:59; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Confirms Div Policy; to Maintain or Increase Div Per Shr Year-on-Year

2024-12-12 05:58; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Sees Low-To-Mid Single-Digit CER Sales Growth Beyond 2025

2024-12-12 05:58; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Sees CHI Core Ebitda Margin in the Mid-Twenties for 2025

2024-12-12 05:58; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Sees Gradual Return to Previous Core Ebitda Margin Beyond 2025

2024-12-12 05:57; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Sees Low-To-Mid Single-Digit CHI Sales Growth for 2025

2024-12-12 05:55; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Sees Core 2025 Ebitda Growth Ahead of Sales Growth

2024-12-12 05:54; UTC

Įsigijimai, susijungimai, perėmimai

Lonza CHF 2025 Sales From Vacaville, Core Ebitda Margin Approaching 30%

2024-12-12 05:54; UTC

Įsigijimai, susijungimai, perėmimai

Lonza CDMO 2025 Outlook Approaching 20% Sales Growth in CER

2024-12-12 05:53; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Sees 2024 Core Ebitda Margin of 27-29%

2024-12-12 05:53; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Sees Flat 2024 CER Sales Growth

2024-12-12 05:52; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Backs 2024 View

2024-12-12 05:52; UTC

Įsigijimai, susijungimai, perėmimai

Lonza: CDMO Business to Be Structured Into Three New Business Platforms

2024-12-12 05:52; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Exit Capsules, Health Ingredients Business at Appropriate Time

2024-12-12 05:51; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Outlines Strategy, New Organizational Structure and Guidance

2024-10-24 06:37; UTC

Rinkos pokalbiai
Uždarbis

Lonza 3Q Update Didn't Surprise -- Market Talk

Lonza Group AG Prognozė

Kainos tikslas

By TipRanks

17.56% į viršų

12 mėnesių prognozė

Vidutinis 666.55 CHF  17.56%

Aukščiausias 744 CHF

Žemiausias 625 CHF

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Lonza Group AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

9

Pirkti

2

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.